Epitope-Specific Serological Assays for RSV: Conformation Matters by Emily Phung, Lauren A. Chang, Kaitlyn M. Morabito, Masaru Kanekiyo, Man Chen, Deepika Nair, Azad Kumar, Grace L. Chen, Julie E. Ledgerwood, Barney S. Graham, Tracy J. Ruckwardt

Get full text

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). by Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team

Get full text

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. by Barney S Graham, Mary E Enama, Martha C Nason, Ingelise J Gordon, Sheila A Peel, Julie E Ledgerwood, Sarah A Plummer, John R Mascola, Robert T Bailer, Mario Roederer, Richard A Koup, Gary J Nabel, VRC 008 Study Team

Get full text

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical... by Uzma N Sarwar, Laura Novik, Mary E Enama, Sarah A Plummer, Richard A Koup, Martha C Nason, Robert T Bailer, Adrian B McDermott, Mario Roederer, John R Mascola, Julie E Ledgerwood, Barney S Graham, VRC 015 study team

Get full text

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). by Michelle C Crank, Eleanor M P Wilson, Laura Novik, Mary E Enama, Cynthia S Hendel, Wenjuan Gu, Martha C Nason, Robert T Bailer, Gary J Nabel, Adrian B McDermott, John R Mascola, Richard A Koup, Julie E Ledgerwood, Barney S Graham, VRC012 Study Team

Get full text

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. by Julie E Ledgerwood, Abbie R Bellamy, Robert Belshe, David I Bernstein, Srilatha Edupuganti, Shital M Patel, Phyllis Renehan, Thad Zajdowicz, Richard Schwartz, Richard Koup, Robert T Bailer, Galina V Yamshchikov, Mary E Enama, Uzma Sarwar, Brenda Larkin, Barney S Graham, VRC 701 study team

Get full text

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in... by Cristina Carter, Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Grace L Chen, Shital M Patel, Patricia Winokur, Robert Belshe, Cornelia L Dekker, Barney S Graham, Julie E Ledgerwood, VRC 703 study team

Get full text

Phase 1 study of pandemic H1 DNA vaccine in healthy adults. by Michelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E Enama, LaSonji A Holman, Robert T Bailer, Melissa B Pearce, Richard A Koup, John R Mascola, Gary J Nabel, Terrence M Tumpey, Richard M Schwartz, Barney S Graham, Julie E Ledgerwood, VRC 308 Study Team

Get full text

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. by Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Myeisha Paskel, Kanta Subbarao, Edwin Anderson, David I Bernstein, Buddy Creech, Harry Keyserling, Paul Spearman, Peter F Wright, Barney S Graham, Julie E Ledgerwood, VRC 702 study team

Get full text

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial by Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood

Get full text

Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings by Kristin L. Boswell, Timothy A. Watkins, Evan M. Cale, Jakob Samsel, Jakob Samsel, Sarah F. Andrews, David R. Ambrozak, Jefferson I. Driscoll, Michael A. Messina, Sandeep Narpala, Christine S. Hopp, Alberto Cagigi, Joseph P. Casazza, Takuya Yamamoto, Tongqing Zhou, William R. Schief, Peter D. Crompton, Julie E. Ledgerwood, Mark Connors, Lucio Gama, Peter D. Kwong, Adrian McDermott, John R. Mascola, Richard A. Koup

Get full text

Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV by Bryan T. Mayer, Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, Nicole Yates, Julie E. Ledgerwood, Kenneth Mayer, Marina Caskey, Michel Nussenzweig, Kathryn Stephenson, Boris Julg, Dan H. Barouch, Magdalena E. Sobieszczyk, Srilatha Edupuganti, Colleen F. Kelley, M. Juliana McElrath, Huub C. Gelderblom, Michael Pensiero, Adrian McDermott, Lucio Gama, Richard A. Koup, Peter B. Gilbert, Myron S. Cohen, Lawrence Corey, Ollivier Hyrien, Georgia D. Tomaras, Yunda Huang

Get full text

High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials by Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Bo Zhang, Lindsay N. Carpp, Craig A. Magaret, Michal Juraska, Peter B. Gilbert, David C. Montefiori, Katharine J. Bar, E. Fabian Cardozo-Ojeda, Joshua T. Schiffer, Raabya Rossenkhan, Paul Edlefsen, Lynn Morris, Nonhlanhla N. Mkhize, Carolyn Williamson, James I. Mullins, Kelly E. Seaton, Georgia D. Tomaras, Philip Andrew, Nyaradzo Mgodi, Julie E. Ledgerwood, Myron S. Cohen, Lawrence Corey, Logashvari Naidoo, Catherine Orrell, Paul A. Goepfert, Martin Casapia, Magdalena E. Sobieszczyk, Shelly T. Karuna, Srilatha Edupuganti

Get full text

Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials by Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Bo Zhang, Lindsay N. Carpp, Craig A. Magaret, Michal Juraska, Peter B. Gilbert, David C. Montefiori, Katharine J. Bar, E. Fabian Cardozo-Ojeda, Joshua T. Schiffer, Raabya Rossenkhan, Paul Edlefsen, Lynn Morris, Nonhlanhla N. Mkhize, Carolyn Williamson, James I. Mullins, Kelly E. Seaton, Georgia D. Tomaras, Philip Andrew, Nyaradzo Mgodi, Julie E. Ledgerwood, Myron S. Cohen, Lawrence Corey, Logashvari Naidoo, Catherine Orrell, Paul A. Goepfert, Martin Casapia, Magdalena E. Sobieszczyk, Shelly T. Karuna, Srilatha Edupuganti

Get full text

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

Get full text

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase... by Katherine V. Houser, Martin R. Gaudinski, Myra Happe, Sandeep Narpala, Raffaello Verardi, Edward K. Sarfo, Angela R. Corrigan, Richard Wu, Ro Shauna Rothwell, Laura Novik, Cynthia S. Hendel, Ingelise J. Gordon, Nina M. Berkowitz, Cora Trelles Cartagena, Alicia T. Widge, Emily E. Coates, Larisa Strom, Somia Hickman, Michelle Conan-Cibotti, Sandra Vazquez, Olga Trofymenko, Sarah Plummer, Judy Stein, Christopher L. Case, Martha Nason, Andrea Biju, Danealle K. Parchment, Anita Changela, Cheng Cheng, Hongying Duan, Hui Geng, I-Ting Teng, Tongqing Zhou, Sarah O'Connell, Chris Barry, Kevin Carlton, Jason G. Gall, Britta Flach, Nicole A. Doria-Rose, Barney S. Graham, Richard A. Koup, Adrian B. McDermott, John R. Mascola, Peter D. Kwong, Julie E. Ledgerwood

Get full text

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine by Joseph P. Casazza, Amelia R. Hofstetter, Pamela J. M. Costner, LaSonji A. Holman, Cynthia S. Hendel, Alicia T. Widge, Richard L. Wu, William R. Whalen, Jennifer Cunningham, Anita Arthur, Xiaolin Wang, Abidemi Ola, Jamie Saunders, Floreliz Mendoza, Laura Novik, Maria C. Burgos Florez, Ana M. Ortega-Villa, Preeti J. Apte, Larisa Strom, Lu Wang, Marjaan Imam, Manjula Basappa, Mursal Naisan, Mike Castro, Jessica F. Trost, Sandeep R. Narpala, Hillary A. Vanderven, Galina V. Yamshchikov, Nina M. Berkowitz, Ingelise J. Gordon, Sarah H. Plummer, Diane L. Wycuff, Sandra Vazquez, Rebecca A. Gillespie, Adrian Creanga, William C. Adams, Kevin Carlton, Jason G. Gall, Adrian B. McDermott, Leonid A. Serebryannyy, Katherine V. Houser, Richard A. Koup, Barney S. Graham, Julie E. Ledgerwood, John R. Mascola, Theodore C. Pierson, Sarah F. Andrews, Masaru Kanekiyo, Lesia K. Dropulic, The VRC 323 study team

Get full text